Switch theme
Sign up to access all valuation multiples
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business.
2006
382
LTM Revenue $234M
LTM EBITDA $54.8M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Harrow has a last 12-month revenue (LTM) of $234M and a last 12-month EBITDA of $54.8M.
In the most recent fiscal year, Harrow achieved revenue of $200M and an EBITDA of $20.0M.
Harrow expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Harrow valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $234M | XXX | $200M | XXX | XXX | XXX |
| Gross Profit | $176M | XXX | $150M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $54.8M | XXX | $20.0M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $21.0M | XXX | $9.1M | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | -$6.7M | XXX | -$17.5M | XXX | XXX | XXX |
| Net Margin | -3% | XXX | -9% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $172M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Harrow's stock price is $28.
Harrow has current market cap of $1.0B, and EV of $1.2B.
See Harrow trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.0B | XXX | XXX | XXX | XXX | $-0.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Harrow has market cap of $1.0B and EV of $1.2B.
Harrow's trades at 6.0x EV/Revenue multiple, and 59.7x EV/EBITDA.
Equity research analysts estimate Harrow's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Harrow has a P/E ratio of -153.8x.
See valuation multiples for Harrow and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | 21.8x | XXX | 59.7x | XXX | XXX | XXX |
| EV/EBIT | 57.0x | XXX | 131.7x | XXX | XXX | XXX |
| EV/Gross Profit | 6.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | -153.8x | XXX | -59.0x | XXX | XXX | XXX |
| EV/FCF | -27.3x | XXX | -19.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHarrow's last 12 month revenue growth is 41%
Harrow's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.4M for the same period.
Harrow's rule of 40 is 49% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Harrow's rule of X is 126% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Harrow and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 41% | XXX | 41% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | 87% | XXX | 175% | XXX | XXX | XXX |
| Rule of 40 | 49% | XXX | 51% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 126% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Harrow acquired XXX companies to date.
Last acquisition by Harrow was XXXXXXXX, XXXXX XXXXX XXXXXX . Harrow acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Harrow founded? | Harrow was founded in 2006. |
| Where is Harrow headquartered? | Harrow is headquartered in United States of America. |
| How many employees does Harrow have? | As of today, Harrow has 382 employees. |
| Who is the CEO of Harrow? | Harrow's CEO is Mr. Mark L. Baum. |
| Is Harrow publicy listed? | Yes, Harrow is a public company listed on NAS. |
| What is the stock symbol of Harrow? | Harrow trades under HROW ticker. |
| When did Harrow go public? | Harrow went public in 2007. |
| Who are competitors of Harrow? | Similar companies to Harrow include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Harrow? | Harrow's current market cap is $1.0B |
| What is the current revenue of Harrow? | Harrow's last 12 months revenue is $234M. |
| What is the current revenue growth of Harrow? | Harrow revenue growth (NTM/LTM) is 41%. |
| What is the current EV/Revenue multiple of Harrow? | Current revenue multiple of Harrow is 5.1x. |
| Is Harrow profitable? | Yes, Harrow is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Harrow? | Harrow's last 12 months EBITDA is $54.8M. |
| What is Harrow's EBITDA margin? | Harrow's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Harrow? | Current EBITDA multiple of Harrow is 21.8x. |
| What is the current FCF of Harrow? | Harrow's last 12 months FCF is -$43.8M. |
| What is Harrow's FCF margin? | Harrow's last 12 months FCF margin is -19%. |
| What is the current EV/FCF multiple of Harrow? | Current FCF multiple of Harrow is -27.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
